Immuron Ltd.
(UNKNOWN : IMRN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.07%177.961.3%$463.06m
CELGCelgene Corporation
0.93%97.411.3%$422.02m
GILDGilead Sciences, Inc.
1.24%67.180.9%$393.30m
BIIBBiogen Inc.
1.96%232.141.3%$354.35m
ILMNIllumina, Inc.
0.89%347.063.5%$270.33m
REGNRegeneron Pharmaceuticals, Inc.
1.43%309.592.6%$232.25m
AAgilent Technologies, Inc.
0.21%70.121.6%$212.53m
VRTXVertex Pharmaceuticals Incorporated
1.53%172.821.9%$197.15m
ARRYArray BioPharma Inc.
56.05%46.188.2%$185.01m
EXASExact Sciences Corporation
0.63%110.4725.3%$184.03m
ALXNAlexion Pharmaceuticals, Inc.
2.26%120.602.0%$176.06m
BMRNBioMarin Pharmaceutical Inc.
4.14%84.194.3%$136.23m
MRTXMirati Therapeutics Inc.
6.14%100.052.5%$113.59m
IONSIonis Pharmaceuticals, Inc.
3.35%64.178.2%$96.21m
INCYIncyte Corporation
4.89%81.512.5%$91.57m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the R&D projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers company activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.